Virbac Past Earnings Performance

Past criteria checks 2/6

Virbac has been growing earnings at an average annual rate of 20.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 7.9% per year. Virbac's return on equity is 13.3%, and it has net margins of 9.7%.

Key information

20.8%

Earnings growth rate

20.8%

EPS growth rate

Pharmaceuticals Industry Growth16.3%
Revenue growth rate7.9%
Return on equity13.3%
Net Margin9.7%
Next Earnings Update13 Sep 2024

Recent past performance updates

Recent updates

Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results

Mar 22
Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results

Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?

Jan 18
Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?

Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up

Dec 27
Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up

Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet

Oct 19
Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?

Sep 26
Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?

Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching

Sep 05
Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching

A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Jun 20
A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?

May 31
Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?

Is Virbac (EPA:VIRP) Using Too Much Debt?

Apr 09
Is Virbac (EPA:VIRP) Using Too Much Debt?

Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?

Feb 28
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?

Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate

Nov 25
Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate

Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?

Oct 14
Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued

Aug 07
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued

These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely

Jun 26
These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely

Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate

May 01
Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate

We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease

Mar 26
We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease

Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate

Jan 26
Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate

Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock

Dec 28
Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock

A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Oct 27
A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Is Virbac (EPA:VIRP) Using Too Much Debt?

Oct 12
Is Virbac (EPA:VIRP) Using Too Much Debt?

Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

Sep 26
Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

Is Virbac SA (EPA:VIRP) Trading At A 22% Discount?

Jul 15
Is Virbac SA (EPA:VIRP) Trading At A 22% Discount?

Is Now The Time To Put Virbac (EPA:VIRP) On Your Watchlist?

Jun 27
Is Now The Time To Put Virbac (EPA:VIRP) On Your Watchlist?

Is Virbac (EPA:VIRP) A Risky Investment?

May 27
Is Virbac (EPA:VIRP) A Risky Investment?

Robust Earnings May Not Tell The Whole Story For Virbac (EPA:VIRP)

Mar 24
Robust Earnings May Not Tell The Whole Story For Virbac (EPA:VIRP)

Are Investors Undervaluing Virbac SA (EPA:VIRP) By 32%?

Mar 12
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 32%?

Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching

Feb 22
Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching

Is Virbac SA (EPA:VIRP) Popular Amongst Insiders?

Feb 03
Is Virbac SA (EPA:VIRP) Popular Amongst Insiders?

Virbac SA's (EPA:VIRP) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 05
Virbac SA's (EPA:VIRP) Stock Is Going Strong: Is the Market Following Fundamentals?

Does Virbac's (EPA:VIRP) Share Price Gain of 96% Match Its Business Performance?

Dec 18
Does Virbac's (EPA:VIRP) Share Price Gain of 96% Match Its Business Performance?

Estimating The Fair Value Of Virbac SA (EPA:VIRP)

Dec 01
Estimating The Fair Value Of Virbac SA (EPA:VIRP)

Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

Nov 18
Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

Revenue & Expenses Breakdown
Beta

How Virbac makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTPA:VIRP Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,2471215730
30 Sep 231,2291205730
30 Jun 231,2101195680
31 Mar 231,2131215630
31 Dec 221,2161225570
30 Sep 221,1841205330
30 Jun 221,1511195130
31 Mar 221,1071165000
31 Dec 211,0641134870
30 Sep 211,0251374730
30 Jun 219851614590
31 Mar 219601484490
31 Dec 209341364390
30 Sep 209441044440
30 Jun 20953724480
31 Mar 20946624510
31 Dec 19938524540
30 Sep 19921434490
30 Jun 19903344450
31 Mar 19886274460
31 Dec 18869204460
30 Sep 1886284420
30 Jun 18854-44380
31 Mar 18858-34400
31 Dec 17862-34420
30 Sep 17871164440
30 Jun 17879354460
31 Mar 17876354490
31 Dec 16872354520
30 Sep 16861304590
30 Jun 16850264660
31 Mar 16851184630
31 Dec 1585394600
30 Sep 15846214410
30 Jun 15839324210
31 Mar 15806483980
31 Dec 14773643750
30 Sep 14752603660
30 Jun 14730563570
31 Mar 14733583560
31 Dec 13736613550
30 Sep 13727613560
30 Jun 13718613560
31 Mar 13706643500

Quality Earnings: VIRP has high quality earnings.

Growing Profit Margin: VIRP's current net profit margins (9.7%) are lower than last year (10%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VIRP's earnings have grown significantly by 20.8% per year over the past 5 years.

Accelerating Growth: VIRP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: VIRP had negative earnings growth (-0.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.5%).


Return on Equity

High ROE: VIRP's Return on Equity (13.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.